A CXCL2 polymorphism is associated with better outcomes in patients with severe sepsis

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2292-2297

  Villar, Jesús ^a,b   Pérez Méndez, Lina ^c   Flores, Carlos ^d   Maca Meyer, Nicole ^c   Espinosa, Elena ^c   Muriel, Arturo ^e   Sangüesa, Rubén ^c   Blanco, Jesús ^e   Muros, Mercedes ^c   Kacmarek, Robert M ^f  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d UNIVERSITY OF CHICAGO   (United States)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f HARVARD UNIVERSITY   (United States)

Author keywords

Acute respiratory distress; CXCL2; Genetic association study; Macrophage inflammatory protein 2; Polymorphism; Sepsis

Indexed keywords

CHEMOKINE; CXCL2 CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; TANDEM REPEAT;

AGED; CHEMOKINE CXCL2; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 34748837923     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000284511.73556.59     Document Type: Article

References (37)

1. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420:885-891
2. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
3. Waterer GW, Quasney MW, Cantor RM, et al: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care 2001; 163:1599-1604
4. Villar J, Maca-Meyer N, Pérez-Méndez L, et al: Understanding genetic predisposition to sepsis. Crit Care 2004; 8:180-189
5. Fink MP, Suter PM: The future of our specialty: Critical care medicine a decade from now. Crit Care Med 2006; 34:1811-1816
6. Wolpe SD, Sherry B, Juers D, et al: Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A 1989; 86:612-616
7. Walley KR, Lukacs NW, Standiford TJ, et al: Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 1997; 65:3847-3851
8. Ebong S, Call D, Nemzek J, et al: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999; 67:6603-6610
9. Lomas-Neira JL, Chung CS, Wesche DE, et al: In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 2005; 77:846-853
10. Flores C, Maca-Meyer N, Pérez-Mendez L, et al: A CXCL2 tandem repeat promoter polymorphism is associated with susceptibility to severe sepsis in the Spanish population. Genes Immun 2006; 7:141-149
11. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
12. Villar J, Manzano JJ, Blazquez MA, et al: Multiple system organ failure in acute respiratory failure. J Crit Care 1991; 6:75-80
13. Cooper DN, Nussbaum RL, Krawczak M: Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 2002; 110:207-208
14. Hattersley AT, McCarthy MI: What makes a good genetic associations study? Lancet 2005; 366:1315-1323
15. Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7:781-791
16. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-829
17. The International HapMap Consortium. The International HapMap project. Nature 2003; 426:789-796
18. Mountain JL, Knight A, Jobin M, et al: SNPSTRs: Empirically derived, rapidly typed, autosomal haplotypes for inference of population history and mutational processes. Genome Res 2002; 12:1766-1772
19. Maca-Meyer N, Villar J, Pérez-Méndez L, et al: A tale of aborigines, conquerors, and slaves: Alu insertion polymorphisms and the peopling of Canary Islands. Ann Hum Genet 2004; 68:600-605
20. Raymon M, Rousset F: GENEPOP (version 1.1.2): Population genetics software for exact tests and ecumenicism. J Hered 1995; 86:248-249
21. Hao K, Li C, Rosenow C, et al: Detect and adjust for population stratification in population-based association study using genomic control markers: An application of Affymetrix Genechip Human Mapping 10K array. Eur J Hum Genet 2004; 12:1001-1006
22. Steffens M, Lamina C, Illig T, et al: SNP-based analysis of genetic substructure in the German population. Hum Hered 2006; 62:20-29
23. Kikuchi A, Yamaya M, Suzuki S, et al: Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet 2005; 116:354-360
24. Grogoryev DN, Finigan JH, Hassoun P, et al: Searching for gene candidates in acute lung injury. Crit Care 2004; 8:440-447
25. Jackson JR, Seed MP, Kircher CH, et al: The co-dependence of angiogenesis and chronic inflammation. FASEB J 1997; 11:457-465
26. Strieter RM, Burdick MD, Gomperts BN, et al: CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16:593-609
27. Serio KJ, Reddy KV, Bigby TD: Lipopolysaccharide induces 5-lipoxygenase activating protein gene expression in THP-1 cells via a NF-κB and C/EBP-mediated mechanism. Am J Physiol Cell Physiol 2005; 288:C1125-C1133
28. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L622-L645
29. Altavilla D, Squadrito G, Minutoli L, et al: Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovasc Res 2002; 54:684-693
30. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
31. Brueckmann M, Hoffmann U, Dvortsak E, et al: Drotrecogin alfa (activated) inhibits NK-kappa B activation and MIP-1 alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004; 53:528-533
32. Texereau J, Pene F, Chiche JD, et al: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:S313-S319
33. Emonts M, Hazelzet JA, de Groot R, et al: Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003; 3:565-577
34. Kerlin BA, Yan SB, Isermann BH, et al: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092
35. Stanilova SA, Miteva LD, Karakolev ZT, et al: Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med 2006; 32:260-266
36. Gong MN, Zhou W, Williams PL, et al: -308GA and TNFB polymorphisms in acute respiratory distress syndrome. Eur Respir J 2005; 26:382-389
37. Gong MN, Thompson BT, Williams PL, et al: Interleukin-10 polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J 2006; 27:674-681